Interferon Gamma Induced Protein 10 (IP-10) in a Clinical Decision Support Protocol in COVID-19 Patients

Completed

• Conditions: COVID-19

• Registration Number: NCT04389645
• Lead Sponsor: MeMed Diagnostics Ltd.

Brief Summary

The proposed project will pilot incorporation of rapid serial measurements of IP-10 into a CDS tool for moderate and severe COVID-19 patients.

The tool was applied to all comers with confirmed COVID-19 diagnosis at a secondary medical center in Israel.

Detailed Description

Not available

Study Timeline

• Study Start: 2020-04-07
• Status Verified: 2020-05
• Primary Completion: 2020-05-12
• Study Completion: 2020-05-12
• Study First Submitted: 2020-05-13
• Study First Submitted QC: 2020-05-14
• Last Update Submitted: 2020-05-14
• Study First Posted: 2020-05-15
• Last Update Posted: 2020-05-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 52

Inclusion Criteria

• PCR- positive for COVID-19

Exclusion Criteria

• <18 years of age

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
IP-10 levels	up to 24 months

Trial Locations

Locations (1)

Rabin Medical Center; 🇮🇱 Petach Tikva, Israel